EntreMed, Inc. (ENMD) announced today the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC).
Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana University serves as the investigator for the study.
Indiana University joins the University of Colorado Cancer Center where the Phase 2 study is already underway. This study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute.
More information about the clinical trial can be found at www.ClinicalTrials.gov.